Company Description
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.
Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms.
Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017.
The company was incorporated in 2011 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Apr 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Lyn Baranowski |
Contact Details
Address: 105 W First Street Boston, Massachusetts 02127 United States | |
| Phone | (206) 707-0340 |
| Website | avalynpharma.com |
Stock Details
| Ticker Symbol | AVLN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1540171 |
| CUSIP Number | 05348Y105 |
| ISIN Number | US05348Y1055 |
| Employer ID | 45-2463191 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lyn Baranowski | Chief Executive Officer, President and Director |
| Douglas R. Carlson | Chief Financial Officer and Chief Business Officer |
| Dr. Melissa Rhodes DABT, Ph.D. | Chief Operating Officer |
| Dr. Howard M. Lazarus M.D. | Chief Medical Officer |
| Cassie Saitow | Senior Director of IR and Corporate Communications |
| Adam H, Golden J.D. | General Counsel and Head of Business Development |
| Dr. Craig Conoscenti M.D. | Senior Vice President of Clinical Development |
| James Bishop | Senior Vice President of Business Operations |
| Dr. Stephen Pham Ph.D. | Senior Vice President of Product Development |
| Michelle Patterson M.B.A., P.M.P. | Senior Vice President of Corporate Planning and Portfolio Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 11, 2026 | SCHEDULE 13G | Filing |
| Aug 6, 2026 | SCHEDULE 13G/A | Filing |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 10-Q | Quarterly Report |
| Jun 3, 2026 | 8-K | Current Report |
| May 8, 2026 | SCHEDULE 13D | Filing |